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Monoclonal antibody BE2 recognizes an antigen found on 
malignant T4 + lymphocytes from cutaneous T-cell lym-
phoma patients (CTCL) . Normal peripheral blood lym-
phocytes do not express detectable levels of BE2 antigen. 
Forty-eight percent of patients with the acquired immu-
nodeficiency syndrome (AIDS) had lymphocyte popula-
tions that were reactive with monoclonal antibody BE2. 
Peripheral blood lymphocytes from healthy homosexuals, 
T be acquired immunodeficiency syndrome (AIDS) was first identifi ed in 1981 as an increased susceptibility to unusual neoplasms and opportunistic infections in youn g homosexual men [1-5]. AIDS was subse-quently described in heterosexual i. v. drug users [6,7], 
hemophiliacs [8,9], blood transfusion recipients [7 ,10], and chil-
dren [11] and consorts of AIDS patients [12] . AIDS patients are 
generall y leukopenic and Iymphopenic. A depletion ofT4 + helper 
T lymphocytes and a relative or absolu te increase in suppressor 
T cells (T8 +) is found in the peripheral blood of AIDS patients 
[1-3,6, 13,14]. Recen t evidence demonstrates that the causative 
agent of AIDS is human T -ceillymphotropic virus type III (HTL V-
1II), a retrovirus that targets the T4 + lymphocyte subset [15,16]. 
HTL V III is a member of the family of retroviruses that includes 
HTLV-I , a virus isolated from patients with the T-cell neoplasm, 
cutaneous T-cell lymphoma (CTCL) [17]. Monoclonal antibody 
BE2 was produced against malignant T4 + lymphocytes obtained 
from a patient with HTLV-I-associated CTCL [1 7, 18] . Since AIDS 
patients have a disease mediated by a T4-tropic retrovirus, it was 
postul ated that the target cells might express the BE2 antigen 
prev iously found on malignant T4 cells from CTCL patients . 
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A bbrevia tions: 
AIDS: acquired immunodefi ciency syndrome 
C M V: cytomcgalovirus 
CTCL: cLltaneoLl S T-cell lymphoma 
EBV: Epstein-Barr vi rus 
HTLV: human T-cclll ymphotropic virus 
patients with classical Kaposi 's sarcoma or viral syndromes 
and healthy normal controls were BE2 - . Double-labeling 
studies demonstrated that BE2 + cells were T lymphocytes . 
This observation demonstrates that some AIDS patients as 
well as CTCL patients have circulating cells that express a 
common lymphocyte abnormality. J lIwest Dermatol 87:28()'" 
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This report demonstrates that approximately 48% of AIDS 
patients have peripheral blood T cells that react with BE2. This 
observation supports a common antigenic abnormality on a target 
T4 + T-cell subset in AIDS and CTCL. 
METHODS 
Patient Selection Epidemiologic, serologic, and clinical in-
form ation on each patient was obtained and correlated with 
monoclonal antibody phenotype. Patients and control groups in-
cluded: (1) 40 AIDS patients with Kaposi's sa rcoma andlor op-
portunistic infections; .(2) 19 asy mptomatic,. apparently healthy 
homosexuals; (3) 5 patIents WIth nonepldemlc, claSSIcal Kaposi's 
sarcoma; (4) 5 patients with active viral infections; and (5) SO 
normal healthy controls . The diagnosis of AIDS was based on 
unexplained immune suppression in a previously healthy member 
of a group considered "at risk for AIDS ." Criteria used included· 
clinical and histopathologic evidence of epidemic Kaposi 's sar~ 
coma [19] andlor recurrent infection by opportunistic pathogens 
associated with AIDS (as defined by the Centers for Disease Con-
trol criteria) [5 ,10). 
Those individuals included in the study group as healthy ho-
mosexuals had no clinical symptoms such as persistent maJaise 
lymphadenopathy, weight loss, diarrhea, or fever of unknow~ 
origin . They did have contagious diseases frequently associated 
with the homosexual lifestyle such as hepatitis A or B, gonorrhea, 
syphilis, amebiasis, and serologic evidence of Epstein-Barr virus 
and cytomega lovirus infection (Table 1) [20). 
The 5 heterosexual patients with classical Kaposi 's sa rcoma 
(Table I) were older (55-88 years) and of Jewish or Italian an-
cestry . Four males and 1 female patient were studied. Four pa-
tients had localized nonaggressive lesions of long duration (x = 
10 years) , while 1 patient had extensive cutaneous lesions without 
identifiable systemic involvement. 
Five patients hos pitalized for active viral syndromes based 011 
rising antibody titers to Epstein-Barr virus (EBV) or cytomeg-
alovirus (CMV) were also studied (Table I) . Fifty normal het-
erosexual male and female volunteers in apparent good health 
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Table I. M onoclonal Antibody Studies 
Subjects T3 T4 T8 DE2 Ratio 4/S 
Health y homosexuals (n = 19) 7S ± 5. 1 48 ± 12 33 ± 12 I ± I 1.7 ± 1.0 
Nonepidemic Kaposi's sarcoma (11 5) 61 ± 16 47 ± 17 IS ± 10 0.55 ± 0.33 3.5 ± 2.2 
11 = 4" 
Viral syndrome (11 = 5) 59 ± 10 40 ± 8 24 ± 7 3 ± 2 1.74 ± 0.4 1 
Normal controls (11 = 50) 69 ± 9 43 ± 8 24 ± 5 2 ± 110 1. 80 ± 0.58 
"One p:lt ic l1t wit h class ical Kaposi's sa rco m a W:l S 13% rC:l ctivc w ith m o noclona l 'lIltibody BE2. 
ItN cga £i vc binding in co mparison w ith the bO ll d in g or no nspecifi c ascites Auid to con tro l lymphocytes x := 1.37 ± 0.97. 
served as an additional contro l g roup (Ta b le I). Info rm ed consent 
in acco rdan ce w ith th e Human In vestiga tion Committee Guide-
lines was obtained from vo lunteer subj ects. 
Monoclonal Antibodies The der iva tio n and charac teri za tion 
of m o no clonal antibod y BE2 has been prev iousl y described [l S]. 
In brief, mono clo nal antibod y BE2 recognizes a m embrane an-
tigen expressed on lym phocytes in the peripheral blood of 75% 
of CTCL patients tested . A sn1311 pop ul atio n of B-cell chro nic 
lymphocy ti c leukemia lymphocytes as we ll as an EB V-trans-
formed B-cell line (G M 1 056) and so m e long-term T-cell lines 
(MOLT 3, HUT 7S) ex press BE2-reactive anti gen . Restin g , mi-
togen- or T3-still1ul ated no rm al lymphocytes do no t exp ress de-
tectab le levels ofBE2 antigen . T he CTC L patient w hose leukemi c 
lymphocytes served as the source of immunogen for the fusion 
resultin g in the development of B E2 antibody, was subsequentl y 
fo und to be infected w ith H TL V-I [1 71. The m o lecu lar weight 
of the antigen detected by m o noclonal antibod y BE2 was deter-
, mined to be 7S,000 [IS] . Other m o noclon als used include: T3 
(Pan T cell ) [1 3], T4 (hel per T-ce ll subset) [1 4J, and TS (cy to-
toxic/suppressor T-cell subset) [13J. 
Itntnunologic Studies Lymphocytes were iso lated by flotation 
o n Ficoll- H ypaque 1211. The cell s were stained by incubation w ith 
the monoclonal antibodies as previously described [lSJ. Ten th ou-
sand lymp hocytes were ana lyzed for surfa ce fluorescence by pas-
sage through a cytofluorograph (30L, O rth o Instrum ents , West-
wood , Massachu set ts) . 
Double-labeling expe riments were performed by first incu-
bating the cells with BE2 (1 : 300 dilution , 3.3 p.g/ ml) m o noclonal 
antibody and then with a secondary rhodamine-labeled rabbit 
antimouse IgG reagent . After was hing , the cells were reincubated 
w ith no rmal m o use serum , washed , and subseq uently res tained 
w ith a fluorescein-conjugated T3 , T4, or T S reagent (1: 50 di-
1 lu tio n , 100 ng/ml). BE2-positive cell s were selected by exami-
nation with an epifluorescent Leitz microscope and assessed for 
bindin g of the second fluorochrome . 
Statistical Analysis Significance was determined by Student's 
b. 6E2- PATIENTS 
N · 21 
Figure 1. Comparison of the percentage ofT3 +, T4 +, and TS + lym-
phocytes in AIDS pat ients who had popu lations of cells reactive with 
monoclonal antibody BE2 (a) or who were DE2 - (b). Grea ter than 5% 
reactivity wi th BE2 was considered positive (i.e. = 2 SO above the 
binding of BE2 to control lymphocytes, x = 2 ± 1). 
RESULTS 
Monoclonal Antibody Studies T he res ults of m o noclonal an-
tibod y pheno typing o n the 19 AI DS patients th at had BE2-rc-
ac ti ve lymph ocyte popu lations is presented in Fig 1 a. Nineteen 
of 40 (4S%) of the AIDS patients were sig nifi can tl y (p :s 0.001) 
rea ctive w ith m onoclonal ant ibody BE2. A representati ve cy to-
fluorograph pattern of BE2 binding to lymph ocy tes from AIDS 
patients is presented in Fi g 2. The T4/TS ratio in BE2 + J nd BE2 -
AIDS patien ts is ' co mpared in Fig 3. The BE2 + popu lation had 
a hig her T4/T S ratio (x = 0.66 ± O.4S) th an the BE2 - patients 
(x = 0.26 ± 0.28) . 
Three .8E2 + AIDS patients were m oni tored repeatedl y over I-
to 3-l11 on th interval s. One patient had 23% BE2 ' lymph ocy tes 
on initi al eva lu ation and 29% BE2-reacti ve lymph ocy tes 2 111 0nths 
later. A second patient 's BE2-reacti ve lymph ocytes rose fro lll 
10% to 24% BE2 + durin g a 3-week interva l. T he third patient 
CTCL EBV-B 
Ascites / Ascites 
AKS AO I 
Ascites Ascites 
FLUORESCENCE INTENSITY 
Figure 2. Cytofluorograph of the binding of monoclonal antibody BE2 
to peripheral blood lymphocytes frol11 a CT L patient and to an EBV-
transformed B cell (EB V-B). The 2 lower graph s show binding of J3 E2 
to peripheral blood lymphocytes from an AIDS patient with Kaposi's 
sa rco ma (AKS), and an AIDS patient with opportunistic infecti on (AOI). 
Ascites fluid from a nonspecific hybridom3 producing imm unoglobulin 
of the same isotype as BE2 was Ll sed as a negative control. 
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Figure 3. Comparison of the ratio of 4/8 positi ve cells in £ E2 + and 
£E2 - AIDS patients. 
presented w ith 21 % BE2- reactive cells. His BE2 + population fell 
to 13% 1 month later. Subseq uently, 3 months after initial tes tin g 
only 5% BE2 + lymphocytes were identified. During this 3-month 
interva l, the patient 's T4 + lymphocyte population also fell from 
26% to 11 %. BE2 reactivity was a persistent observation in these 
patients and paralleled the disease prog ression in patient 3. His 
loss of T 4 + lymphocytes and BE2 + lymphocytes was accom-
panied by a deterioration in clinical course and th e patient died 3 
months later. 
Peripheral blood lymphocytes fro m 5 elderly patients with clas-
sical Kaposi's sa rcoma (Table I) served as a control group for 
AIDS patients w ith Kaposi's sarcom a. N ormal numbers of pe-
riph eral blood lymphocytes (x = 2909 ± 1211) and T3 + T cells 
were found in these subj ects. There w as a decreased percentage 
of T8 + lymphocytes in the blood of these patients. Decreased 
T8 + cells in the class ical Kapos i's sarcoma patients resulted in an 
elevated T4/T8 ra tio, which may relate to the advanced age of 
these indi viduals [22]. Four of th e 5 cl assical Kaposi's sa rcoma 
patients were BE2 - , 1 patient w ith the most extensive disease 
was BE2 reactive . 
To determine w hether the expression of BE2 antigen was re-
lated to vira l infection, lymphocytes from patients w ith viral 
syndromes (determined by rising EBV or C MV titers) were tes ted. 
No in crease in BE2-reactive cells was identi fied in these patients 
(Ta ble I). Lymphocytes from 50 normal controls were evaluated 
and shown to be BE2 - . 
Double-Labeling Studies Lymphocytes from AIDS patients 
were double-labeled w ith BE2 and T-cell specifi c monoclonals 
to determine whether these cells expressed o th er T-cell markers. 
Lymphocytes fro m 4 patients were exa mined fo r coincident bind-
ing of monoclonal antibody BE2 and pan T cell o r T-cell subset 
specific reagents (T able II). In all cases, the BE2-reactive lym-
phocytes were T cells as determined by their binding ofT3. The 
Table II. Double Labeling Studies of Lymphocy tes from 
BE2-Reactive AIDS Patients (n = 5) 
T3 + T4 + T8+ T3 -
an d and and and 
T3 + T4+ T8 + £E2 + £E2 + <> £E2 + £E2 + £E2 + 
19 9 18 12 11 6 7 0 
60 21 18 0 
71 33 12 14 13 0 
34 10 11 
77 63 20 21 40 5 0 
"Cells were selected fo r BE2 reacti vity under red Au orescence and then exa mined 
for binding of the second ftuo rchrolllc un der green fluo rescence; 200 cells were 
coun ted per slide. 
T HE JO URNAL OF INVESTIGAT IVE DERMATOLOGy 
majority of BE2 + cell s were T 4-reacti ve; however, if suffi cien t 
BE2 + cell s were examined some T8 +, BE2-reacti ve lymphocytes 
could be identifi ed . 
D ISC USSI O N 
BE2-reactive lymphocy tes were present in 48% of the AI DS p a-
tients tes ted. None of the normal contro l population, healthy 
homosexuals, patients WIth VIral mfec tlons, o r 4 of 5 patien ts 
with classica l Kaposi's sa rcoma had lymphocytes that reacted s ig_ 
nificantl y w ith monoclonal antibody BE2. T herefore, in AIDS 
as well as in CT C L, BE2 ex pression appears to be correlated w ith 
an abnorm ality of lymphocy tes of the T-cell class . 
BE2 reacti vity occurs on lymphocytes from patients w ith the 
various clinical presentations that comprise the subgroups o f A IDS 
patients, including: hom osex ual, heterosexual, and bisexual p a-
tients w ith and w ithout Kapos i's sa rcoma and associated oppor_ 
tunistic infection, i. v. heroin users, and transfu sion recipien ts . 
This observation supports a commonality o f disease process an d 
imm une response in AIDS. In reactive patients, in creased B E2 
reacti vity was associated w ith higher T4/T 8 ratios. In 1 patien t 
studied sequentiall y, disease progression was associated w ith ~ 
marked depletion of T4 ;' cell s and a concordant fa ll in BE2 reac_ 
ti vity. These findin gs suggest that loss of T 4 + cells may result 
in decreased BE2 reactivity, and that BE2 reactivity occurs in 
patients w ith primary AIDS w ho have no t to tall y lost the T4 + 
subset. Therefore, patients w ith late-.stage AIDS Illa y no t react 
w ith monoclonal antibody BE2. In this regard 5 AIDS patien ts 
who had to tall y los t all T lymphocytes were BE2 - (data n ot 
presented) . 
Epstein-Barr virus o r C MV infection docs not appear to be the 
stimulus that tri ggers BE2 expression since patients w ith active 
infections w ith these viruses were BE2 - . In addition, C MV and 
EB V infections arc prevalent in health y homosexuals and the 
majority of AIDS patients [1 ,2]. Although these patients had 
elevated humoral antibody titers to these viruses or clinica l evi-
dence of vi ra l infection, there was no reacti vity with mono clonal 
antibody BE2. 
T he presence o f H T L V-I infection in CTCL and some AIDS 
patients sugges ted th at BE2 reactivity mi ght be ca used by this 
virus [1 7,23]. H owever, humoral titers to H T LV-l , P24 anti gen 
were found in only 2 of the BE2-reactive AI DS patients (data not 
presented) . C onvincing evidence has been presented th at HTL V-
III or the related lymphadenopathy-associated retrovirus [1 5,1 6] 
is th e ca usal agent of AIDS. T he BE2 antigen may represent a 
normal cellular produ ct whose expression is induced by retrovi ral 
infection. Restri cti on of the BE2 an tigen to lymphocytes fr0111 
CT C L and AI DS patients and absence of this antigen from normal 
restin g o r activa ted lymphocytes, or from lymphocytes of E B V_ 
and C MV-infected controls supports the interpre tation that ret-
rovira l infection may be one of the stimulii th at tri ggers a cell 
population to express BE2-reactive anti gen . 
In this regard, th e confi rm ation o f BE2 restriction to the T-
cell populati on w as important since AIDS patients have a high 
in cidence of EBV infection [1 ,2] and an EBV-transformed B-ce11 
line w as shown to be BE2+. Double-l abeling studies revealed that 
the BE2-reactive cells in AIDS patients were T cells of either the 
helper or suppressor class. Therefore BE2 positivity is restricted 
to T lymphocytes in AIDS patients and no t related to EBV in-
fection of B cells. 
An alternative explanation fo r BE2 reactivity in AIDS and CTCl 
may be restriction of this anti gen to a small subset of normal T 
lymphocytes that are expanded in response to chroni c antigen 
chall enge in these diseases . T he level of BE2 expression on 1-2% 
of the normal T-cell population would be below the detection 
level of cytoAuorograph y or radi oimmunoassay techniques. An 
antigen-responsive T-cell subset has been postulated as the target 
population for neoplas ti c transformation in CT C L [24]. T he large 
vari ety of antigenic insults to which AIDS patients are exposed 
raises the possibility that a particular antigen-res ponsive T - cell 
subset may also become expanded in these patients. This antigen-
VOL. 87, N O.2 AUGUST 1986 
reactive T - cell subset may be the cell population identified by 
BE2 antibody. Further studies directed toward iso lation of the 
BE2 + subset in AIDS and CTCL w ill facilitate oLlr understandin g 
of the origin of the BE2-reactive ant igen on the T-cell surface . 
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